Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone65-6236-3388
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.41 million
Profitability
Miscellaneous
Employees250
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions
What is Wave Life Sciences' stock symbol?
Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."
How were Wave Life Sciences' earnings last quarter?
Wave Life Sciences Ltd (NASDAQ:WVE) issued its quarterly earnings data on Monday, July, 29th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.11. The company had revenue of $7.63 million for the quarter, compared to the consensus estimate of $15.76 million. Wave Life Sciences had a negative return on equity of 120.41% and a negative net margin of 861.41%. View Wave Life Sciences' Earnings History.
When is Wave Life Sciences' next earnings date?
What price target have analysts set for WVE?
6 equities research analysts have issued 12 month target prices for Wave Life Sciences' shares. Their predictions range from $33.00 to $65.00. On average, they expect Wave Life Sciences' share price to reach $49.50 in the next year. This suggests a possible upside of 132.0% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.
What is the consensus analysts' recommendation for Wave Life Sciences?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.
What are Wall Street analysts saying about Wave Life Sciences stock?
Here are some recent quotes from research analysts about Wave Life Sciences stock:
- 1. According to Zacks Investment Research, "WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. " (8/3/2019)
- 2. HC Wainwright analysts commented, "Our $33 target is based on a risk-adjusted, sum-of-the-parts DCF analysis: beta of 1.16, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.0%, and tax rate of 15% beginning in FY 2030, and is now 100% leveraged to the company’s CNS portfolio. Risks to our target include: commercial, reimbursement, regulatory, along with clinical and manufacturing. WAVE Life Sciences Ltd." (7/31/2019)
Has Wave Life Sciences been receiving favorable news coverage?
News headlines about WVE stock have been trending positive recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Wave Life Sciences earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Wave Life Sciences.
Who are some of Wave Life Sciences' key competitors?
Some companies that are related to Wave Life Sciences include Arena Pharmaceuticals (ARNA), The Medicines (MDCO), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), PTC Therapeutics (PTCT), Genmab A/S (GMAB), Amicus Therapeutics (FOLD), Myokardia (MYOK), Agios Pharmaceuticals (AGIO), Reata Pharmaceuticals (RETA), Zogenix (ZGNX), Emergent Biosolutions (EBS), Zai Lab (ZLAB), Uniqure (QURE) and Xencor (XNCR).
What other stocks do shareholders of Wave Life Sciences own?
Who are Wave Life Sciences' key executives?
Wave Life Sciences' management team includes the folowing people:
- Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)
- Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)
- Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)
- Dr. Takeshi Wada, Scientific Advisor (Age 57)
- Mr. Keith C. Regnante, Chief Financial Officer (Age 49)
Who are Wave Life Sciences' major shareholders?
Wave Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.90%), Janus Henderson Group PLC (9.90%), BlackRock Inc. (5.29%), Price T Rowe Associates Inc. MD (3.19%), Vanguard Group Inc. (1.15%) and Northern Trust Corp (0.77%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.
Which institutional investors are selling Wave Life Sciences stock?
WVE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Price T Rowe Associates Inc. MD, Wells Fargo & Company MN, D. E. Shaw & Co. Inc., UBS Asset Management Americas Inc., Allianz Asset Management GmbH, Foresite Capital Management III LLC and Cubist Systematic Strategies LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.
Which institutional investors are buying Wave Life Sciences stock?
WVE stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, BlackRock Inc., Nuveen Asset Management LLC, United Services Automobile Association, Bailard Inc., Platinum Investment Management Ltd. and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Wave Life Sciences.
How do I buy shares of Wave Life Sciences?
Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Wave Life Sciences' stock price today?
One share of WVE stock can currently be purchased for approximately $21.34.
How big of a company is Wave Life Sciences?
Wave Life Sciences has a market capitalization of $731.56 million and generates $14.41 million in revenue each year. The company earns $-146,650,000.00 in net income (profit) each year or ($5.06) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.View Additional Information About Wave Life Sciences.
What is Wave Life Sciences' official website?
How can I contact Wave Life Sciences?
Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]
MarketBeat Community Rating for Wave Life Sciences (NASDAQ WVE)
MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
